RUBICON RESEARCH (RUBICON) Share Price Falls 2.21% Today

RUBICON RESEARCH Share Price fell to Rs 1,786.30 on 03 September 2026, down Rs 40.45 or 2.21% from the previous close of Rs 1,826.75, taking the company’s market capitalisation to Rs 30,127.63 crore. The move has put the Large Cap healthcare stock in focus in today’s market update, especially as the verified data shows a clear intraday decline from the opening level.

For investors searching RUBICON RESEARCH Share Price Today or RUBICON RESEARCH Stock News, the key point is straightforward: the stock opened at Rs 1,834.00, touched a high of Rs 1,834.00, slipped to a low of Rs 1,784.95 and was trading near that lower band at the time of this update. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind today’s decline. What stands out instead is the combination of premium valuation, strong profitability ratios and a meaningful gap between the current price and longer-term moving averages, which keeps the stock relevant on Univest screens. Investors may now monitor whether this weakness stays to one session or starts changing the broader price structure.

RUBICON RESEARCH (RUBICON) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,786.3
Previous Close	Rs 1,826.75
Today's Move	-Rs 40.45 (-2.21%)
Open	Rs 1,834
High	Rs 1,834
Low	Rs 1,784.95
Turnover	Rs 1.15 crore
Market Capitalisation	Rs 30,127.63 crore
Market Cap Category	Large Cap

Today’s price action shows a weak session from the opening tick. RUBICON RESEARCH Share Price opened at Rs 1,834.00, which also marked the day’s high, and then moved lower through the session to a day low of Rs 1,784.95 before trading at Rs 1,786.30. Against the previous close of Rs 1,826.75, that translates into a decline of Rs 40.45 or 2.21%.

This intraday pattern matters because the stock did not build on its opening level; instead, it drifted lower after starting at the top of the day’s range. The spread between the high of Rs 1,834.00 and the low of Rs 1,784.95 shows a session range of just over Rs 49, while turnover stood at Rs 1.15 crore. With a market capitalisation of Rs 30,127.63 crore and a Large Cap tag, today’s decline is attracting attention more for the change in session tone than for any verified company-specific trigger in the supplied data. That makes the next step in RUBICON RESEARCH Share Price analysis a closer look at how current pricing sits against its profitability and valuation profile.

RUBICON RESEARCH (RUBICON) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 30,127.63 crore
P/E Ratio	104.92x
P/B Ratio	22.53x
ROE	27.84%
ROCE	29.22%
EPS	Rs 17.41
Book Value Per Share	Rs 81.09
Dividend Yield	0.08%

The direct fundamental picture is mixed rather than simple. On one side, RUBICON RESEARCH Share Price is supported by strong return ratios: ROE stands at 27.84% and ROCE at 29.22%, both comfortably above many broader industry reference points. EPS is Rs 17.41, which shows the earnings attributable to each share, while book value is Rs 81.09 per share, indicating the accounting net worth backing each share. The dividend yield is 0.08, reflecting a modest historical payout relative to the current market price.

On the other side, valuation is demanding. The stock trades at a P/E ratio of 104.92 and a P/B ratio of 22.53. Those are elevated multiples in absolute terms and therefore investors tracking RUBICON RESEARCH Fundamental Analysis will likely focus on whether strong profitability is sufficient to justify the premium. The gap between price and book value is especially notable, with the current stock price far above the book value per share of Rs 81.09. In short, today’s RUBICON RESEARCH Share Price Fall is drawing interest because the company combines premium valuation with high return metrics, a setup that often keeps institutional and retail market watchers engaged on Univest even during a down session.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	104.92x
Benchmark Median P/E	31.97x
Benchmark Average P/E	48.6x
Benchmark P/E Range	3.49x to 648.54x
Company P/B Ratio	22.53x
Benchmark Median P/B	2.87x
Benchmark Average P/B	4.35x
Company ROE	27.84%
Benchmark Median ROE	11.79%
Benchmark Average ROE	11.15%
Company ROCE	29.22%
Benchmark Median ROCE	13.63%
Benchmark Average ROCE	13.69%
Company Market Capitalisation	Rs 30,127.63 crore
Benchmark Median Market Cap	Rs 727.27 crore
Benchmark Average Market Cap	Rs 14,141.34 crore

RUBICON RESEARCH operates in Healthcare, specifically the Pharmaceuticals & Drugs industry, and the sector benchmark data gives useful context for today’s move. The supplied comparison covers the same industry and spans 201 companies, making it a broad reference set for assessing valuation and profitability against listed peers.

The valuation premium is clear. The company’s P/E of 104.92 is well above the industry median of 31.97 and also above the average of 48.60 across 169 companies with available P/E data. It also sits far closer to the upper end of the industry range of 3.49 to 648.54 than to the middle. A similar pattern appears on price-to-book: RUBICON’s P/B of 22.53 is sharply above the industry median of 2.87 and average of 4.35, within a reported range of -10.61 to 27.80 across 200 companies.

Profitability, however, is stronger than the benchmark. ROE of 27.84% is much higher than the industry median of 11.79% and average of 11.15%, while ROCE of 29.22% exceeds the median of 13.63% and average of 13.69% across 200 companies. Size is also meaningful: the company’s market cap of Rs 30,127.63 crore is above the industry median of Rs 727.27 crore and the average of Rs 14,141.34 crore, though still far below the maximum of Rs 4,63,179.62 crore. For Univest readers, that makes the stock notable as a relatively large player with above-benchmark returns but also a valuation that already prices in significant quality.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,63,179.62	38.34	5.36	14.85	19.11
Divi's Laboratories	DIVISLAB	2,43,301.95	83.79	13.88	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,88,622.52	87.28	21.21	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,16,114.43	25.44	4.26	19.69	21.39
Cipla	CIPLA	1,14,554.33	33.87	3.25	11.83	16

Against major Pharmaceuticals & Drugs peers, RUBICON RESEARCH Share Price reflects one of the richer valuation setups in the comparison set. Its P/E of 104.92 is above Sun Pharmaceutical Industries at 38.34, Divi's Laboratories at 83.79, Torrent Pharmaceuticals at 87.28, Zydus Lifesciences at 25.44 and Cipla at 33.87. Its P/B of 22.53 is also above Sun Pharma’s 5.36, Divi’s 13.88, Zydus’s 4.26 and Cipla’s 3.25, and only marginally above Torrent Pharmaceuticals at 21.21.

Profitability tells a different story. RUBICON’s ROE of 27.84% is ahead of Sun Pharma at 14.85%, Divi’s at 16.19%, Torrent at 26.76%, Zydus at 19.69% and Cipla at 11.83%. Its ROCE of 29.22% is also above Sun Pharma’s 19.11%, Divi’s 21.51%, Torrent’s 19.27%, Zydus’s 21.39% and Cipla’s 16.00%. Market-cap-wise, RUBICON at Rs 30,127.63 crore is much smaller than these large pharma peers, whose values range from Rs 1,14,554.33 crore for Cipla to Rs 4,63,179.62 crore for Sun Pharma. That relative picture suggests investors are paying a premium for profitability, but the premium is substantial and therefore closely watched during any share price decline.

Why Investors Are Watching RUBICON RESEARCH

• RUBICON RESEARCH Share Price fell 2.21% in one session to Rs 1,786.30 from Rs 1,826.75.
• The stock opened at Rs 1,834.00, which was also the day’s high, before sliding to Rs 1,784.95.
• ROE of 27.84% and ROCE of 29.22% are stronger than industry median and average levels.
• P/E of 104.92 and P/B of 22.53 place the stock at a clear premium to industry benchmarks and key peers.
• Its Rs 30,127.63 crore market capitalisation keeps it relevant in the Large Cap healthcare space tracked on Univest.

About RUBICON RESEARCH

RUBICON RESEARCH is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. Based on the supplied market data, the company sits in the Large Cap category with a market capitalisation of Rs 30,127.63 crore, placing it above the industry median company size. For investors following RUBICON RESEARCH Stock News, the current market interest is tied less to a disclosed event in the dataset and more to how the stock combines high return ratios with premium valuation within the listed pharma universe. Univest users typically track such companies closely because sector leadership and valuation discipline often move together in this industry.

Track RUBICON RESEARCH Share Price on Univest

UseRUBICON RESEARCH (RUBICON) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

You can track RUBICON RESEARCH Share Price on Univest for live price moves, market capitalisation, valuation ratios, profitability indicators, 52-week levels and broader market insights. Univest also helps investors compare pharma stocks across peer valuations, sector benchmarks and price action, making it easier to follow RUBICON RESEARCH Share Price Today in a structured and data-led format without relying on speculation.

Frequently Asked Questions

Why did RUBICON RESEARCH Share Price fall today?

Ans. The supplied data confirms that RUBICON RESEARCH Share Price fell 2.21% to Rs 1,786.30 from Rs 1,826.75. However, the verified dataset does not establish any company-specific catalyst for today’s decline, only the price movement itself.

What is RUBICON RESEARCH Share Price Today?

Ans. RUBICON RESEARCH Share Price Today was Rs 1,786.30 at the time of the update. The stock was down Rs 40.45 or 2.21% versus the previous close of Rs 1,826.75, keeping it in focus among market watchers.

How did the stock trade during the session?

Ans. The stock opened at Rs 1,834.00, which was also the day’s high, and later slipped to a low of Rs 1,784.95. Trading near the session low indicated a weaker intraday tone than the opening level suggested.

Is RUBICON RESEARCH a large-cap stock?

Ans. Yes, the company is classified as a Large Cap stock in the supplied dataset. Its market capitalisation stood at Rs 30,127.63 crore, which is well above the industry median market cap of Rs 727.27 crore.

How expensive is RUBICON RESEARCH on P/E basis?

Ans. The stock trades at a P/E ratio of 104.92. That is far above the Pharmaceuticals & Drugs industry median of 31.97 and average of 48.60, indicating that the market assigns the company a premium valuation multiple.

How does RUBICON RESEARCH compare on P/B ratio?

Ans. RUBICON RESEARCH has a P/B ratio of 22.53. This is substantially above the industry median of 2.87 and average of 4.35, showing that the share price is valued at a large premium to book value.

Are profitability ratios strong for RUBICON RESEARCH ?

Ans. Profitability ratios are strong in the supplied data. ROE is 27.84% and ROCE is 29.22%, both comfortably above the industry medians of 11.79% and 13.63%, as well as the corresponding industry averages.

What do EPS, book value and dividend yield show?

Ans. EPS stands at Rs 17.41, book value per share is Rs 81.09 and dividend yield is 0.08. Together, these figures show earnings support, accounting net worth and a modest historical payout relative to price.

How does RUBICON RESEARCH compare with major pharma peers?

Ans. The company’s P/E of 104.92 is above peers such as Sun Pharma, Divi’s, Torrent, Zydus and Cipla. However, its ROE of 27.84% and ROCE of 29.22% are stronger than those peer figures in the supplied comparison.

What should investors monitor next in RUBICON RESEARCH ?

Ans. Investors may monitor whether the stock stabilises after falling from the day’s high of Rs 1,834.00 to Rs 1,784.95. Valuation levels, sector benchmarks and follow-through in price action remain the key data points to watch.